Year-end Sale % OFF 
Abstract
Lung cancer, the most common of malignant tumors, is typically of the non-small cell (NSCLC) type. T-cell-based immunotherapies are a promising and powerful approach to treating NSCLCs. To characterize the CD8+ T cells of non-small cell lung cancer, we re-analyzed the published RNA-Seq gene expression profiles of 36 CD8+ T cell isolated from tumor (TIL) samples and 32 adjacent uninvolved lung (NTIL) samples. With an advanced Monte Carlo method of feature selection, we identified the CD8+ TIL specific expression patterns. These patterns revealed the key dysfunctional genes and pathways in CD8+ TIL and shed light on the molecular mechanisms of immunity and use of immunotherapy.
Highlights
Lung cancer, the most common of malignant tumors, is typically (∼80%) of the non-small cell (NSCLC) type (Zhan et al, 2017)
As we described in the methods, the Monte Carlo feature selection method was adopted to analyze the gene expression profiles of 36 TIL samples and 32 NTIL samples
The goal was to identify the discriminative genes between TIL samples and NTIL samples
Summary
The most common of malignant tumors, is typically (∼80%) of the non-small cell (NSCLC) type (Zhan et al, 2017). Tumor-infiltrating lymphocytes are considered to play a critical role in the immune response to many human solid cancers. In the immune response to cancer, these tumor-infiltrating CD8+ T cells have the potential to recognize specific antigens that are presented by the MHC class I receptor on cancer cells and target them for destruction. Studies have shown that immune infiltration by CD8+ cytotoxic T cells is significantly correlated with improved clinical outcome in non-small cell lung cancer (NSCLC) (Johnson et al, 2000; Welsh et al, 2005; AlShibli et al, 2008; Kawai et al, 2008). High density of tumor-infiltrating lymphocytes usually signified strong prognostic value (Hiraoka et al, 2006; Al-Shibli et al, 2008; Kawai et al, 2008; Schalper et al, 2015)
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
